Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of an Olanzapine Based Dexamethasone-sparing Regimen in Breast Cancer Patients With Metabolic-risk Factors: A Randomized, Controlled Trial

NCT07743827 is registered in ClinicalTrials.gov with Alexandria University as lead sponsor.

NCT NCT07743827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07743827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of an Olanzapine Based Dexamethasone-sparing Regimen in Breast Cancer Patients With Metabolic-risk Factors: A Randomized, Controlled Trial
Lead sponsor
Alexandria University
Phase
Not applicable
Overall status
Recruiting
Start date
May 10, 2026
Completion date
October 15, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, dexamethasone, olanzapine